Travere Therapeutics achieved a significant milestone as the FDA granted full approval for Filspari, their drug for IgA nephropathy (IgAN). Previously approved under conditional status, the updated label removes the proteinuria (urine protein level) requirement, meaning the drug can now be prescribed to patients at varying risks of disease progression. This adjustment will enable Filspari to reach more patients and is expected to boost physician confidence in prescribing the treatment.
The drug was initially approved in early 2023 based on clinical data showing its effectiveness in reducing proteinuria, a key marker for kidney function. Filspari’s ability to slow kidney function decline over time, as demonstrated in a modified analysis of patient outcomes, supported the push for full approval. CEO Eric Dube emphasized that this expanded access will increase Filspari's market presence, especially as doctors gain trust in its ability to preserve kidney function.
The approval comes as competition heats up in the IgAN treatment space, with drugs like Calliditas Therapeutics’ Tarpeyo and Novartis’ Fabhalta also in the market. Filspari, however, stands out with its dual-action mechanism, combining endothelin receptor and angiotensin receptor inhibition in a single pill. Despite the added competition, Travere believes the convenience of Filspari's one-pill regimen will resonate strongly with both patients and physicians. However, the drug's liver toxicity monitoring requirement remains, though Travere is collecting data to potentially adjust this in the future.
Click here to read the original news story.